186 Matching Annotations
  1. Last 7 days
  2. Apr 2021
    1. Table 1:Potential treatments

      Blockade of NFkB/TLR4 pathway may also be beneficial due to the SARS-CoV-2 activation of TLR4 https://doi.org/10.1101/2020.12.18.423427

      Anti-viral neuraminidase inhibitors such as Oseltamivir or Zanamivir reduced neutrophil hyper-activation (via inhibition of host neuraminidase) and may present a new targeted therapeutic strategy https://doi.org/10.1101/2020.11.12.379115

      IL-18 blockade may represent a therapeutic option for COVID-19 as it may participate in hyperinflammation and tissue damage https://doi.org/10.1002/jcp.30008

      Increasing evidence that NK cells could be used as therapies for COVID-19 https://doi.org/10.1186/s40164-021-00199-1 as well as evidence for targeting specific mutants of COVID-19 with ‘off-the shelf’ CAR-NK cells https://doi.org/10.1101/2021.01.14.426742

  3. Mar 2021
    1. Rosendaal, F. R. (2020). Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. International Journal of Antimicrobial Agents, 106063. https://doi.org/10.1016/j.ijantimicag.2020.106063

  4. Feb 2021
    1. There are both broadly immunosuppressive approaches, such as high-dose corticosteroids, and more novel targeted approaches that go after inflammatory cytokine proteins
    2. There are also a few effective treatments for cytokine storms despite the fact that we still do not know exactly which treatments will ultimately be developed and recommended across the board for COVID-19 related cytokine storms.
    1. Nogués, X., Ovejero, D., Quesada-Gomez, J. M., Bouillon, R., Arenas, D., Pascual, J., Villar-Garcia, J., Rial, A., Gimenez-Argente, C., Cos, M. L., Rodriguez-Morera, J., Campodarve, I., Guerri-Fernandez, R., Pineda-Moncusí, M., & García-Giralt, N. (2021). Calcifediol Treatment and COVID-19-Related Outcomes (SSRN Scholarly Paper ID 3771318). Social Science Research Network. https://doi.org/10.2139/ssrn.3771318

  5. Jan 2021
  6. Dec 2020
    1. Emily. J. Miller. - FDA {@FDASpox} (2020) Convalescent plasma has shown to be beneficial for 35% of patients. This risk reduction figure - shown in chart below - is from @MayoClinic data from expanded access program that was analyzed by FDAA for the emergency use authorization announced today. Twitter. Retrieved from: https://twitter.com/FDASpox/status/1297706985039835136

  7. Oct 2020
  8. Sep 2020
    1. Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., Pardo-Hernandez, H., Rochwerg, B., Lamontagne, F., Han, M. A., Liu, Q., Agarwal, A., Agoritsas, T., Chu, D. K., Couban, R., Darzi, A., Devji, T., Fang, B., Fang, C., … Brignardello-Petersen, R. (2020). Drug treatments for covid-19: Living systematic review and network meta-analysis. BMJ, 370. https://doi.org/10.1136/bmj.m2980

    1. Ip, A., Ahn, J., Zhou, Y., Goy, A. H., Hansen, E., Pecora, A. L., Sinclaire, B. A., Bednarz, U., Marafelias, M., Mathura, S., Sawczuk, I. S., Underwood, J. P., Walker, D. M., Prasad, R., Sweeney, R. L., Ponce, M. G., LaCapra, S., Cunningham, F. J., Calise, A. G., … Goldberg, S. L. (2020). Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study. MedRxiv, 2020.08.20.20178772. https://doi.org/10.1101/2020.08.20.20178772

  9. Aug 2020
    1. Hogan, A. B., Jewell, B. L., Sherrard-Smith, E., Vesga, J. F., Watson, O. J., Whittaker, C., Hamlet, A., Smith, J. A., Winskill, P., Verity, R., Baguelin, M., Lees, J. A., Whittles, L. K., Ainslie, K. E. C., Bhatt, S., Boonyasiri, A., Brazeau, N. F., Cattarino, L., Cooper, L. V., … Hallett, T. B. (2020). Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: A modelling study. The Lancet Global Health, 0(0). https://doi.org/10.1016/S2214-109X(20)30288-6

    1. Chen, Y., Yang, W.-H., Huang, L.-M., Wang, Y.-C., Yang, C.-S., Liu, Y.-L., Hou, M.-H., Tsai, C.-L., Chou, Y.-Z., Huang, B.-Y., Hung, C.-F., Hung, Y.-L., Chen, J.-S., Chiang, Y.-P., Cho, D.-Y., Jeng, L.-B., Tsai, C.-H., & Hung, M.-C. (2020). Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro. BioRxiv, 2020.08.14.250258. https://doi.org/10.1101/2020.08.14.250258

    1. Sherrard-Smith, E., Hogan, A. B., Hamlet, A., Watson, O. J., Whittaker, C., Winskill, P., Ali, F., Mohammad, A. B., Uhomoibhi, P., Maikore, I., Ogbulafor, N., Nikau, J., Kont, M. D., Challenger, J. D., Verity, R., Lambert, B., Cairns, M., Rao, B., Baguelin, M., … Churcher, T. S. (2020). The potential public health consequences of COVID-19 on malaria in Africa. Nature Medicine, 1–6. https://doi.org/10.1038/s41591-020-1025-y

    1. Horby, P., Mafham, M., Linsell, L., Bell, J. L., Staplin, N., Emberson, J. R., Wiselka, M., Ustianowski, A., Elmahi, E., Prudon, B., Whitehouse, A., Felton, T., Williams, J., Faccenda, J., Underwood, J., Baillie, J. K., Chappell, L., Faust, S. N., Jaki, T., … Landray, M. J. (2020). Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. MedRxiv, 2020.07.15.20151852. https://doi.org/10.1101/2020.07.15.20151852

  10. Jul 2020